{"preliminary_commentary":{"by_channel":{"x_thread":11,"youtube":1,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04589845\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["entrectinib"],["alectinib"],["atezolizumab"]],"indication":"solid tumors","name":"TAPISTRY","nct_id":"NCT04589845","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tapistry-nct04589845. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants with metastatic or advanced solid tumors, with the exception of non-small cell lung cancer (NSCLC), will receive entrectinib once daily (QD) in repeated 28-day cycles at a dose of 600 milligram per day (mg/day) for adults and pediatric participants with a body surface area (BSA) ≥ 1.51 square meter (m\\^2). The total dose of daily entrectinib administration for pediatric participants with BSA \\< 1.51 m\\^2 will be lower.","label":"Cohort A: ROS Proto-oncogene 1 (ROS1) Fusion-positive Tumors (Excluding NSCLC)","type":"EXPERIMENTAL"},{"description":"Participants with metastatic or advanced solid tumors will receive entrectinib, QD in repeated 28-day cycles at a dose of 600 mg/day for adults and pediatric participants with a BSA ≥ 1.51 m\\^2. The total dose of daily entrectinib administration for pediatric participants with BSA \\< 1.51 m\\^2 will be lower.","label":"Cohort B: Neurotrophic Tyrosine Receptor Kinase (NTRK) 1/2/3 Fusion-positive Tumors","type":"EXPERIMENTAL"},{"description":"Participants with metastatic or advanced solid tumors, with the exception of NSCLC, will receive alectinib at a dosage of 600 mg, orally, twice a day (BID), taken with food, in repeated 28-day cycles.","label":"Cohort C: Anaplastic Lymphoma Kinase (ALK) Fusion-positive Tumors (Excluding NSCLC)","type":"EXPERIMENTAL"},{"description":"Participants with metastatic or advanced solid tumors will receive atezolizumab intravenously (IV) at a fixed dose for participants aged ≥ 18 years, and 15 milligrams per kilogram (mg/kg) (maximum 1200 mg) for participants aged \\< 18 years on Day 1 of each 21-day cycle. Note: Cohort D has been closed.","label":"Cohort D: TMB-high Tumors","type":"EXPERIMENTAL"},{"description":"Participants with metastatic or advanced solid tumors will receive ipatasertib orally, QD at the starting dose of 400 mg in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent. For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants \\< 35 kilograms (kg), 300 mg for participants ≥ 35 and \\< 45 kg, 400 mg for those ≥ 45 kg orally QD in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent. Note: Cohort E has been closed.","label":"Cohort E: Protein Kinase B (AKT) 1/2/3 Mutant-positive Tumors","type":"EXPERIMENTAL"},{"description":"Participants with metastatic or advanced solid tumors will receive trastuzumab emtansine IV at a dose of 3.6 mg/kg every 21 days.\n\nNote: Cohort F has been closed as of protocol version 7 because enrollment and participant follow-up have been completed.","label":"Cohort F: Human Epidermal Growth Factor Receptor 2 (HER2) Mutant-positive Tumors","type":"EXPERIMENTAL"},{"description":"Participants with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) multiple mutant-positive tumors will receive inavolisib (GDC-0077) QD at a starting dose of 9 mg by mouth (PO) in repeated 28-day cycles. Note: Cohort H has been closed for enrollment.","label":"Cohort H: PIK3CA Multiple Mutant-positive Tumors","type":"EXPERIMENTAL"},{"description":"Participants with proto-oncogene B-Raf (BRAF) class II mutant/fusion-positive tumors (adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib, PO, BID with adequate water (more than 200 milliliters \\[mL\\]). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle. Note: Cohort I has been closed.","label":"Cohort I: BRAF Class II Mutant or Fusion-positive Tumors","type":"EXPERIMENTAL"},{"description":"Participants with BRAF class III mutant-positive tumors (adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib PO BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle. Note: Cohort J has been closed for enrollment.","label":"Cohort J: BRAF Class III Mutant-positive Tumors","type":"EXPERIMENTAL"},{"description":"Participants with RET fusion-positive tumors will self-administer pralsetinib orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric participants ≥ 12 and \\< 18 years of age. A treatment cycle consists of 4 weeks (28 days). Note: Cohort K has been closed.","label":"Cohort K: Rearranged During Transfection (RET) Fusion-positive Tumors (Excluding NSCLC)","type":"EXPERIMENTAL"},{"description":"Participants with kirsten rat sarcoma virus (KRAS) G12C-positive tumors will self-administer divarasib (GDC-6036) orally at home (except on clinic days).","label":"Cohort L: KRAS G12C-positive Tumors (Excluding NSCLC and Colorectal Cancer [CRC])","type":"EXPERIMENTAL"},{"description":"Participants with ATM LOF tumors will self-administer camonsertib orally at home (except on clinic days). Note: Cohort M has been closed.","label":"Cohort M: Ataxia-telangiectasia Mutated (ATM) Loss of Function (LOF) Tumors","type":"EXPERIMENTAL"},{"description":"Participants with methyltransferase SET (Su(var) 3-9) Enhancer of zest and Trithorax) domain-containing 2 (SETD2) LOF tumors will self-administer camonsertib orally at home (except on clinic days). Note: Cohort N has been closed.","label":"Cohort N: SETD2 LOF Tumors","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2032-09-25","type":"ESTIMATED"},"conditions":["Solid Tumors"],"enrollment":{"count":920,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Entrectinib","otherNames":["Rozlytrek"],"type":"DRUG"},{"name":"Entrectinib","otherNames":["Rozlytrek"],"type":"DRUG"},{"name":"Alectinib","otherNames":["Alecensa"],"type":"DRUG"},{"name":"Atezolizumab","otherNames":["Tecentriq"],"type":"DRUG"},{"name":"Ipatasertib","otherNames":[],"type":"DRUG"},{"name":"Trastuzumab emtansine","otherNames":["Kadcyla"],"type":"DRUG"},{"name":"Inavolisib","otherNames":["GDC-0077"],"type":"DRUG"},{"name":"Belvarafenib","otherNames":[],"type":"DRUG"},{"name":"Pralsetinib","otherNames":["Gavreto (US)"],"type":"DRUG"},{"name":"Divarasib","otherNames":["GDC-6036"],"type":"DRUG"},{"name":"Camonsertib","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-04","lead_sponsor":"Hoffmann-La Roche","official_title":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2032-09-25","type":"ESTIMATED"},"primary_outcomes":[{"measure":"All Cohorts: Independent Review Committee (IRC)-assessed Objective Response Rate (ORR) Based on Confirmed Objective Response (OR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)","timeFrame":"Approximately up to 12 years"}],"references":[{"citation":"Bagchi A, Chiang J, Pinto S, Dhanda S, Gajjar A. Infant-Type Hemispheric Gliomas: A Review of Clinical, Radiologic, Histopathologic, and Molecular Features. J Natl Compr Canc Netw. 2025 Nov;23(11):e257064. doi: 10.6004/jnccn.2025.7064.","pmid":"41213248","type":"DERIVED"},{"citation":"Desai AV, Bagchi A, Armstrong AE, van Tilburg CM, Basu EM, Robinson GW, Wang H, Casanova M, Andre N, Campbell-Hewson Q, Wu Y, Cardenas A, Ci B, Ryklansky C, Devlin CE, Meneses-Lorente G, Wulff J, Hutchinson KE, Gajjar A, Fox E. Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. Eur J Cancer. 2025 May 2;220:115308. doi: 10.1016/j.ejca.2025.115308. Epub 2025 Feb 22.","pmid":"40086048","type":"DERIVED"}],"start_date":{"date":"2021-01-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","url":"https://clinicaltrials.gov/study/NCT04589845"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tapistry-nct04589845"}